These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 29229612)
1. Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy. Deng KQ; Zhao GN; Wang Z; Fang J; Jiang Z; Gong J; Yan FJ; Zhu XY; Zhang P; She ZG; Li H Circulation; 2018 Apr; 137(14):1486-1504. PubMed ID: 29229612 [TBL] [Abstract][Full Text] [Related]
2. Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4. Zhao GN; Zhang P; Gong J; Zhang XJ; Wang PX; Yin M; Jiang Z; Shen LJ; Ji YX; Tong J; Wang Y; Wei QF; Wang Y; Zhu XY; Zhang X; Fang J; Xie Q; She ZG; Wang Z; Huang Z; Li H Nat Med; 2017 Jun; 23(6):742-752. PubMed ID: 28481357 [TBL] [Abstract][Full Text] [Related]
3. ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR. Liu A; Xie H; Tian F; Bai P; Weng H; Liu Y; Liu W; Tang L; You H; Zhou N; Shu X Hypertension; 2023 Dec; 80(12):2674-2686. PubMed ID: 37846580 [TBL] [Abstract][Full Text] [Related]
4. Nuclear Localization Leucine-Rich-Repeat Protein 1 Deficiency Protects Against Cardiac Hypertrophy by Pressure Overload. Zong J; Li FF; Liang K; Dai R; Zhang H; Yan L; Liu JL; Xu LH; Qian WH Cell Physiol Biochem; 2018; 48(1):75-86. PubMed ID: 30001530 [TBL] [Abstract][Full Text] [Related]
5. Cardiac-Specific EPI64C Blunts Pressure Overload-Induced Cardiac Hypertrophy. Zhu X; Fang J; Gong J; Guo JH; Zhao GN; Ji YX; Liu HY; Wei X; Li H Hypertension; 2016 May; 67(5):866-77. PubMed ID: 27021007 [TBL] [Abstract][Full Text] [Related]
6. Sp1-induced LncRNA CTBP1-AS2 is a novel regulator in cardiomyocyte hypertrophy by interacting with FUS to stabilize TLR4. Luo X; He S; Hu Y; Liu J; Chen X Cardiovasc Pathol; 2019; 42():21-29. PubMed ID: 31220774 [TBL] [Abstract][Full Text] [Related]
7. RIP2 deficiency attenuates cardiac hypertrophy, inflammation and fibrosis in pressure overload induced mice. Zhao CH; Ma X; Guo HY; Li P; Liu HY Biochem Biophys Res Commun; 2017 Nov; 493(2):1151-1158. PubMed ID: 28698147 [TBL] [Abstract][Full Text] [Related]
8. Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway. Li CY; Zhou Q; Yang LC; Chen YH; Hou JW; Guo K; Wang YP; Li YG Basic Res Cardiol; 2016 Mar; 111(2):19. PubMed ID: 26891723 [TBL] [Abstract][Full Text] [Related]
9. Triad3A attenuates pathological cardiac hypertrophy involving the augmentation of ubiquitination-mediated degradation of TLR4 and TLR9. Lu X; He Y; Tang C; Wang X; Que L; Zhu G; Liu L; Ha T; Chen Q; Li C; Xu Y; Li J; Li Y Basic Res Cardiol; 2020 Feb; 115(2):19. PubMed ID: 32008145 [TBL] [Abstract][Full Text] [Related]
10. SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1-Dependent Manner. Qian Q; Hu F; Yu W; Leng D; Li Y; Shi H; Deng D; Ding K; Liang C; Liu J J Am Heart Assoc; 2023 Apr; 12(7):e028628. PubMed ID: 36974751 [TBL] [Abstract][Full Text] [Related]
11. NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity. Zhang X; Lei F; Wang XM; Deng KQ; Ji YX; Zhang Y; Li H; Zhang XD; Lu Z; Zhang P J Am Heart Assoc; 2020 Aug; 9(16):e016419. PubMed ID: 32805187 [TBL] [Abstract][Full Text] [Related]
12. Growth/differentiation factor 1 alleviates pressure overload-induced cardiac hypertrophy and dysfunction. Zhang Y; Zhang XF; Gao L; Liu Y; Jiang DS; Chen K; Yang Q; Fan GC; Zhang XD; Huang C Biochim Biophys Acta; 2014 Feb; 1842(2):232-44. PubMed ID: 24275554 [TBL] [Abstract][Full Text] [Related]
13. Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload. Li L; Chen W; Zhu Y; Wang X; Jiang DS; Huang F; Wang L; Xiang F; Qin W; Wang Q; Zhang R; Zhu X; Li H; Chen X Hypertension; 2014 Jul; 64(1):94-102. PubMed ID: 24777975 [TBL] [Abstract][Full Text] [Related]
14. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Ha T; Li Y; Hua F; Ma J; Gao X; Kelley J; Zhao A; Haddad GE; Williams DL; William Browder I; Kao RL; Li C Cardiovasc Res; 2005 Nov; 68(2):224-34. PubMed ID: 15967420 [TBL] [Abstract][Full Text] [Related]
15. Different roles of BAG3 in cardiac physiological hypertrophy and pathological remodeling. Jia P; Wu N; Yang H; Guo Y; Guo X; Sun Y Transl Res; 2021 Jul; 233():47-61. PubMed ID: 33578031 [TBL] [Abstract][Full Text] [Related]
16. HINT1 (Histidine Triad Nucleotide-Binding Protein 1) Attenuates Cardiac Hypertrophy Via Suppressing HOXA5 (Homeobox A5) Expression. Zhang Y; Da Q; Cao S; Yan K; Shi Z; Miao Q; Li C; Hu L; Sun S; Wu W; Wu L; Chen F; Wang L; Gao Y; Huang Z; Shao Y; Chen H; Wei Y; Chen F; Han Y; Xie L; Ji Y Circulation; 2021 Aug; 144(8):638-654. PubMed ID: 34098726 [TBL] [Abstract][Full Text] [Related]
17. TRIM-containing 44 aggravates cardiac hypertrophy via TLR4/NOX4-induced ferroptosis. Wu L; Jia M; Xiao L; Wang Z; Yao R; Zhang Y; Gao L J Mol Med (Berl); 2023 Jun; 101(6):685-697. PubMed ID: 37119283 [TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor receptor-associated factor 3 is a positive regulator of pathological cardiac hypertrophy. Jiang X; Deng KQ; Luo Y; Jiang DS; Gao L; Zhang XF; Zhang P; Zhao GN; Zhu X; Li H Hypertension; 2015 Aug; 66(2):356-67. PubMed ID: 26034202 [TBL] [Abstract][Full Text] [Related]
19. Tumor Necrosis Factor- Yao R; Kong L; Yang C; Du J; Zhao G; Li Y Oxid Med Cell Longev; 2022; 2022():9469143. PubMed ID: 35528518 [TBL] [Abstract][Full Text] [Related]
20. Tripartite motif 32 prevents pathological cardiac hypertrophy. Chen L; Huang J; Ji Y; Zhang X; Wang P; Deng K; Jiang X; Ma G; Li H Clin Sci (Lond); 2016 May; 130(10):813-28. PubMed ID: 26884348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]